

Elmutaz H Taha¹, Ibrahim A Ali², Omer A Musa²

¹Department of Physiology, Faculty of Medicine, Dongola University, Sudan.

²Department of Physiology, Faculty of Medicine, National Ribat University, Sudan.

*Hemamedicine@gmail.com

*Corresponding Author: Elmutaz H Taha, Department of Physiology, Faculty of Medicine, Dongola University, Sudan.

Abstract

Background: Diabetes mellitus is a leading cause of illness and death. Pulmonary function test PFT has assumed a key role in epidemiological studies investigating the incidence, natural history and causality of lung disease.

Methods: A cross sectional study was conducted in The National Ribat Teaching Hospital and Jabir Abualiz Specialized Diabetes Center in Khartoum state to measure the respiratory muscle power in 31 diabetic patients (case group) and 30 non-diabetics patients (control groups). Pulmonary function tests were measured by using Digital Spirometer-Micro-Plus version.

Results: lung function parameters between diabetic patients and their matched control group show no significant differences between the means of FVC, FEV1 and FEV1/FVC. However, diabetic patients showed significant reduction in PEFR.

Conclusion: Exercise and well control of diabetes helped in preserving normal respiratory muscle power. Continuous reasonable exercise with good control is highly recommended for all diabetics.

Keywords: FEV1, FVC, PFT, Diabetes mellitus.

INTRODUCTION

Diabetes mellitus is a leading cause of illness and death. Lung function test is the most basic, widely used, pulmonary function test (PFT). It typically assesses lung volumes and flows and is ideally suited to describe the effects of obstruction or restriction on lung function. (1)It is now regarded as an integral component of any respiratory medical surveillance programs. PFT has assumed a key role in epidemiological studies investigating the incidence, natural history and causality of lung disease. (2) The role of lung function test in diabetic patients is further increased when a new strategy (Inhaled insulin) has been introduced for the treatment of diabetes mellitus. (3) In normal healthy non smoker subject after the age of 35, the expected decline in lung function, Forced Expiratory Volume in 1 sec (FEV1) is 25-30 ml/year. However, the average rate of decline of lung function in diabetic patients as measured by Forced Expiratory Volume in 1 sec (FEV1) is 71 ml/year. (4) McKeever et al. $^{(5)}$ observed that increase in mean HbA $_{_{1c}}$ is associated with decrease in lung function parameters FVC &

FEV1. They hypothesized that impaired glucose autoregulation is associated with impaired lung function.

In study of Sultan Meo et al. observed that Subjects with diabetes showed a significant reduction in forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) relative to their matched controls, concluded that Pulmonary function in a specific ethnic group of patients with diabetes was impaired as evidenced by a decrease in FVC and FEV1 compared to pulmonary function in matched controls. Stratification of results by years of disease revealed a significant correlation between duration of disease and a decline in pulmonary function. (6) In other study of Ali Mo et al demonstrated that mean of the percentage of the predicted values of FVC and FEV1, were significantly (p<0.001) lower in diabetic patients than their matched. Again they concluded that the ventilatory function of lung may be reduced in type 2 diabetes which may be related to the duration of the disease.⁽⁷⁾ For this reason respiratory muscle endurance also decreases in diabetes mellitus. (6) Again, the increased ratio of FEV1/FVC (%) in diabetic

patients of longer duration is due to disproportionate reduction of FVC and FEV1, which indicate that long-standing hyperglycemia may cause predominantly restrictive type of lung disorder. All these changes may be due to glycation of the chest wall and bronchial tree protein. This is further supported by negative correlation of FVC and FEV1 and positive correlation of FEV1/FVC% with longer duration of diabetes. The negative correlation of FVC and FEV1 with duration of diabetes indicate that long standing hyperglycemia may intensify the devastating effect of the disease.⁽⁶⁾

The present study was designed to observe the effect of diabetes mellitus on lung function in patients with diabetes mellitus belonging to specific society namely Sudanese in the center of Sudan.

MATERIALS AND METHODS

A cross sectional study was conducted to measure the pulmonary function tests in 31 diabetic patients (case group) and 30 non-diabetics patients (control groups). The study was conducted in The National Ribat Teaching Hospital and Jabir Abualiz Specialized Diabetes Center which are located in Khartoum state - the capital of Sudan. This study group includes all Sudanese diabetic patients attending to the diabetic clinics in The National Ribat Teaching Hospital and Jabir Abualiz Specialized Diabetes Center during the period of study. Age range from 20 to 75 years, and mean duration of disease was 10.60 ± 1.11 years. Their duration of disease ranged from 1 to 30 years. Patients with diabetes were individually matched with controls for age, height, and weight. Matching between both groups was within ±3 years for age, ±4 centimeters for height, and ±5 kilograms for weight. Overall, there were no significant differences in anthropometric means in combined or stratified data. Age, and height were given more emphasis for matching, as these two relate better to lung function than weight.

11 Controls were from a similar community with the same socioeconomic status relative to patients with diabetes. All subjects had never smoked. All subjects completed a questionnaire, which included anthropometric data and a consent form. Subjects with gross abnormalities of the vertebral column or thoracic cage, known history of acute or chronic respiratory infections, neuromuscular disease, malignancy, cardiopulmonary disease, or a history of major abdominal or chest surgery were excluded from the study. In addition, subjects with current or previous drug or tobacco (smoked or chewed) addictions were excluded. Patients with complications of diabetes such as neuropathy, nephropathy, and retinopathy were also excluded from the study.

TECHNIQUE OF PULMONARY FUNCTION TESTS

A spirometer is an apparatus for measuring the volume of air inspired and expired by the lungs; Figure (1). The subject was asked to take a deep breath (maximum inspiration), and expire hard and forcible as long as possible into the spirometer. The tests were performed (with each subject in the standing position). The tests were repeated three times after adequate rest. Patients were trained about the entire maneuver and were encouraged to practice this maneuver before doing the pulmonary function tests. The parameters that were measured included force vital capacity (FVC), force expiratory volume in 1 second (FEV1), FEV1/FVC, and peak expiratory flow rate (PEFR) the best reading of the three was taken.



Fig 1. Digital spirometer

DATA ANALYSIS

Data was analyzed by statistical package for social science (SPSS) version 20, and any significance different between case and control groups in pulmonary function tests were identified by using t-test among sociodemographic and medical characteristic. Data had been displayed by tables and histogram.

ETHICAL CLEARANCE

Ethical clearance was obtained from the scientific committee of the university and from the Hospital

RESULTS

In this study 61 adult subjects were included, 54.10% (34) male, and 45.9% (27) female . 31 diabetic (17 males and 14 females) and 30 control (17 male and 13 female) Figure (2).




Fig 2. Sex distribution among total study group

Figure (3) showed that most of the subjects 37.7% (23 subjects) were in the age group 51- 60 years, 32.8 % (20 subjects) were in the age group 41-50 years and 29.5% (18 subjects) were in the age group 30-40 years.

Figure (4) showed that most of diabetic patients

74.2% (23 patients) included in this study have DM for 1 – 5 years. Patients with DM for more than 10 years (3 patients) have been well controlled on regular treatment and perform exercise daily for at least one-hour walking for the last 10 years compared to the rest.




Fig 3. Age distribution among study population




Fig 4. Duration of diabetes mellitus among case group

Table (1) Summarizes the comparison of lung function parameters between diabetic patients and their FVC. However, diabetic patients showed significant matched control group. There were no significant reduction in Peak Expiratory flow rate PEFR.

differences between the means of FVC, FEV1 and FEV1/

Table 1. lung function and anthropometric data of total diabetic patients (31) compared with their matched controls (30)

Parameters	DM	Control	Dyralya	
Parameters	mean +- SEM n (31)	Mean +- SEM n (30)	P. value	
Age (years)	36.1+- 7.47	36.8+- 6.81	.823	Ns
Height (cm	168.73+- 2.142	168 +- 9.243	.930	Ns
Weight (kg	70.7 +- 3	78.233 +- 2.25	.121	Ns
FVC (L)	3.26 +147	3.38 +135	.751	Ns
FEV1 (L)	2.65 +13	2.714 +117	.74	Ns
PEFR (L)	322.66 +- 25.7	368.53 +- 23	.03	S
FEV1/FVC (%)	90.6 +- 1.261	89.2 +- 1.024	.756	Ns

Table (2) Summarizes the comparison of lung function parameters between diabetic patients with duration of disease 1-10 years and their matched control group. There were no significant differences between the means of FVC, FEV1 and FEV1/FVC. However, diabetic patients showed significant reduction in PEFR.

Table 2. show the lung function and anthropometric data for diabetic patients with duration of disease 1-10 years compared with their matched controls.

Parameters	DM mean +- SEM n (28)	Control Mean +- SEM n (30)	P. value	
Age (years)	35.75+- 7.47	36.8+- 6.81	.786	Ns
Height (cm	164.65+- 2.142	168 +- 9.243	.430	Ns
Weight (kg	69.4 +- 3	78.233 +- 2.25	.101	Ns
FVC (L)	3.00 +147	3.38 +135	.751	Ns
FEV1 (L)	2.62 +13	2.714 +117	.63	Ns
PEFR (L)	287.82 +- 25.7	368.53 +- 23	.009	S
FEV1/FVC (%)	89.25 +- 1.261	89.9 +- 1.024	.756	Ns

Table (3) Summarizes the comparison of lung function parameters between diabetic patients with duration of disease 1-5 years and their matched control group.

There was no significant differences between the means of FVC, FEV1 and FEV1/FVC. However, diabetic patients showed a significant reduction in PEFR.

Table 3. lung function and anthropometric data for diabetic patients with duration of disease 1-5 years compared with their matched controls.

Down store	DM	Control	Davoluo	
Parameters	mean +- SEM n (23)	Mean +- SEM n (30)	P. value	
Age (years)	35.1+- 7.47	36.8+- 6.81	.723	Ns
Height (cm	166.7 +- 2.142	168 +- 9.243	.630	Ns
Weight (kg	74 +- 3	78.233 +- 2.25	.221	Ns
FVC (L)	2.88 +147	3.38 +135	.451	Ns
FEV1 (L)	2.566 +13	2.714 +117	.4	Ns
PEF (L)	260.261 +- 25.7	368.53 +- 23	.003	S
FER (%)	88.7 +- 1.261	89.9 +- 1.024	.756	Ns

There were no significant differences between the means of the lung function parameters of diabetic patients compared with their matched control. table (4).

Table 4. *lung function and anthropometric data for diabetic patients with duration of disease from 6-10 years compared with their matched controls.*

Parameters	DM Mean +- SEM n (5)	Control Mean +- SEM n (30)	P. value	
Age (years)	36.4+- 9.55	36.8+-6.81	.920	Ns
Height (cm)	162.6+- 6.57	168 +- 1.7	.275	Ns
Weight (kg)	64.8 +- 3.33	78.23 +-2.251	.025	S
FVC (L)	3.124 +4465	3.381 +134	.820	Ns
FEV1 (L)	2.686 +381	2.714 +117	.931	Ns
PEFR (L)	315.4 +- 67	368.53 +- 23	.402	NS
FEV1/FVC (%)	89.8 +- 4.17	89.9 +- 1.03	.842	Ns

Diabetic patients with duration of disease more than 10 years showed a significant increase in FEV₁ compared to their matched control.

However, there was no significant difference in pulmonary function and anthropometric data (table 5).

Table 5. Anthropometric and lung function data among diabetic patients with duration of disease more than 10 years compared with matched control.

	DM	Control	P. value	
Parameters	mean+-SEM n (3)	Mean+- SEMn (30)		
Age (years)	36.8+- 81	34.2 +- 9.81	.832	Ns
Height (cm)	175.6 +- 4.33	168.0 +- 1.68	.170	Ns
Weight (kg)	73.33 +88	78.23 +- 2.23	.503	Ns
FVC (L)	3.896 +18	3.38 +134	.057	Ns
FEV1 (L)	3.673 +3	2.714 +117	.018	S
PEFR (L)	492.33 +- 68.3	368.53 +- 23	.112	NS
FEV1/FVC (%)	93.33 +- 3.84	89.9 +- 1.03	.241	Ns




Fig 5. The average mean of PEF among diabetics with different duration and control group.

Figure 5 showed the average mean of PEF between diabetics and control.

Exercise activity in case group (diabetic) was low with percentage 45.2% (14 patients), while 54.8% (17 patients) are not performing exercise (figure 6).

Patients, who perform exercise, walk for half an hour, but not regularly. However, three patients with

duration of disease more than 10 years perform exercise (walking) for at least one hour daily for more than 10 years .

Depending on exercise performance diabetic patients those practice exercise showed slight increase (not significance) in all pulmonary function data as shown in table (6).




Fig 6. Exercise performance among diabetic patients

Table 6. Lung function data among diabetic patients with exercise performance and those not practicing exercise (N=31)

Exercise	Yes	No		
Parameters	Mean ⁻⁺ SEM N (14)	Mean+_ SEM N (17)	P. value	
FVC (L)	3.26 ± 0.2	2.852 +- 0.18	.121	Ns
FEV1 (L)	2.953 ± 0.2	2.47 +152	.062	Ns
PEFR (L)	342.714 +-39.87	249.5 +- 30.32	.068	Ns
FEV1/FVC (%)	91.28 +- 1.67	87.70 +- 1.95	.134	Ns

There was no significant difference among the means of lung function parameters between the diabetic their matched control as shown in table (7).

Table 7. Lung function data among diabetic patients with exercise performance compared with their matched control.

Exercise	Yes	Control	D volue	
Parameters	Mean ⁻⁺ SEM N (14)	Mean +- SEM n (30)	P. value	
FVC (L)	3.26 +2	3.381 +134	.621	Ns
FEV1 (L)	2.953 +2	2.714 +117	.4 62	Ns
PEF (L)	342.714 +-39.87	368.53 +- 23	.168	Ns
FEV1/FVC (%)	91.28 +- 1.67	89.9 +- 1.03	.534	Ns

Depending on exercise performance diabetic patients reduction in PEFR compared with their matched without exercise performance revealed a significant control as shown in table (8).

Table 8. Lung function data among diabetic patients without exercise performance compared with their matched control.

Exercise	No	Control		
Parameters	Mean+_ SEM N (17)	Mean +- SEM n (30)	P. value	
FVC (L)	2.852 +18	3.381 +134	.08	Ns
FEV1 (L)	2.47 +152	2.714 +117	.082	Ns
PEFR (L)	249.5 +- 30.32	368.53 +- 23	.05	S
FEV1/FVC (%)	87.70 +- 1.95	89.9 +- 1.03	.334	Ns

According to vitamin supplementary most of the vitamin, while 38.70% (12 patients) use vitamin diabetic patients 61.30% (19 patients) don't use regularly as shown in figure (7).




Fig 7. Vitamin supplementary status among diabetic patients.

Table 9. *vitamin supplementary among diabetic patients*

Exercise	Yes	No		
Parameters	Mean ⁻ SEM n (12)	Mean ⁺ - SEM n (19)	P. value	
FVC (L)	3.064 +224	2.99 +182	.813	Ns
FEV1 (L)	2.695 ⁺ 198	2.69 +170	.983	Ns
PEFR (L)	309.916 +-36.908	280.052 +- 35.039	.578	Ns
FEV1/FVC (%)	89.33 +- 2.129	89.315 + 1.432	.994	Ns

Table (9) illustrated there were no significant differences in lung function parameters among diabetics patients according to vitamin supplementary. Although there is slight increase in those with vitamin supplementary.

DISCUSSION

This study was conducted among type II diabetic patients (31) and their control (30). The results showed that diabetic patients with duration of disease less than 5 years, there was a significant reduction in the PEFR (260.2 +-25.7) p value < .05 compared to their control group (368.5 +- 23), which is not in agreement with study of sultan Meo et al ⁽⁶⁾,who reported that there was no significant difference between the means of any lung function data among diabetics and their control.

On the other hand this finding in agreement of our study Ali, Mo. et al;⁽⁷⁾ reported that the mean percentage of predicted values of FVC and FEV1 in diabetics were significantly lower than their control. McKeever T, et al ⁽⁵⁾ showed the same result as they observed that increase in mean HbA_{1c} is associated with decrease in lung function parameters FVC & FEV1. They hypothesized that impaired glucose autoregulation is associated with impaired lung function.

Diabetic patients with duration of disease from 5 to 10 years revealed no obvious reduction in all pulmonary functions data compared to their control, which is not in the same line of Sultan Meo et al, who reported that patients with diabetes did show a significant reduction in FVC. On the other hand in diabetics according to the duration more than 10 years of disease showed a significant increase (p value a.o5) in the average means of FEV1 (3.673 +- .3) compared to their matched control (2.714 +-.117), This finding is not in agreement with findings of Sultan Meo et al, who showed that there was a significant decline in FVC and FEV1 in type 2 diabetic patients. However, Ali Mo et al demonstrated that diabetic patients with duration of disease more than 10 years had a significant high percentage of PEFR compared to their matching control, which is in disagreement to our result showed that there were no significant differences between diabetic patients and their control in the predicted value of PEFR. According to exercise diabetic subjects without exercise performance showed slight increase (not significant) in pulmonary function data. This is in agreement with the findings of Leem Romer et al (9) who reported that in athlete's racing bicycle,

respiratory muscle power was increased by 35 W every 3 min starting from 95 W.

No significant values were obtained in diabetic patients with vitamin supplementary on the pulmonary function tests compared with diabetic patients without vitamin supplementary. As the number is limited, more diabetic should be included in another study.

CONCLUSION

Exercise and well control of diabetes helped in preserving normal respiratory muscle power. This could be considered a pilot study and more investigation of more numbers of DM with different duration of disease and level of exercise needs to be performed. Continuous reasonable exercise with good control is highly recommended for all diabetics.

REFERENCES

- [1] Ruppel GL (1997). Pulmonary function testing. Trends and techniques. Resp. Care Clinics. North America. 3: 155-181.
- [2] McKay, Ray. T. and Horvath, Edward, P (1984). Pulmonary function testing in industry. In: Occupational Medicine. Edited by Carl, Zenz., O, Bruca. Dickerson. Edward, P. Horvath. Mosby London, Third edition, pp. 229.
- [3] Meo S, Al-Drees A, Arif M, Al-Rubean K (2006). Lung function in type 2 Saudi diabetic patients. Saudi Med J. 27 (3): 338-43.
- [4] Davis WA, Knuiman M, Kendall P, Grange V, Davis M (2004); Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. Mar; 27(3):752-7.
- [5] McKeever T, Weston P, Hubbard R, Fogarty A (2005). Lung Function and Glucose Metabolism: An Analysis of Data from the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology; 161 (6): 546-556.
- [6] Sultan A. Meo, 1 Abdul Majeed Al Drees, 1 Jehangeer Ahmed, 2 Sayed Fayaz Ahmed Shah, 2 Khalid Al-Regaiey, 1 Ashraf Husain, 1 and Khalid Al-Rubean, 3 (2007). Effect of Duration of Disease on Ventilatory Function in an Ethnic Saudi Group of Diabetic Patients: J Diabetes Sci Technol; 1(5):711-717

- [7] Ali MO1, Begum S2, Begum N3, Ali T4, Ferdousi S5 and Begum A6 (2009): FVC, FEV1 and FEV1/FVC% in Type 2 Diabetes and Their Relationships with Duration of the Disease J Bangladesh Soc Physiol. Dec; 4 (2): 81-87.
- [8] Park SW, Goodpaster BH, Strotmeyer ES, Rekeneire N, Harris TB, Schwartz AN, Tylavsky FA,
- Newman AB (2006). Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes. The Health, Aging and Body Composition Study. Diabetes; 55: 1813-1818.
- [9] Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, Sackner MA. Breathing patterns. Diseased subjects. Chest 1983; 84: 286–294.

Citation: Elmutaz H Taha, Ibrahim A Ali and Omer A Musa. *Effect of Diabetes Mellitus on the Pulmonary Function Tests in Sudanese Diabetic Patients. Archives of Pulmonology and Respiratory Medicine. 2018; 1(1): 50-58.*

Copyright: © 2018 **Elmutaz H Taha, Ibrahim A Ali and Omer A Musa.** This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.